We are live on ! Find out more
PYPD icon

PolyPid

14 hedge funds and large institutions have $155K invested in PolyPid in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

214% more capital inflows, than outflows

Capital inflows: $58.2K | Capital outflows: $18.5K

27% more funds holding

Funds holding: 11 → 14 (+3)

0.52% less ownership

Funds ownership: 1.62% → 1.1% (-0.52%)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
14
Holders Change
+3
Holders Change %
+27.27%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

PYPD Hedge Fund Activity: Q2 2023 in Review

14 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in PolyPid (PYPD) for Q2 2023, worth a combined $155K — up 5% from $148K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new PYPD positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 4 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $15K. The largest seller was Connective Capital Management, exiting entirely with an estimated $11.2K sold.

  • 14 institutional investors held PolyPid (PYPD) as of Q2 2023, up from 11 in Q1 2023.
  • Funds reported $155K of PolyPid stock for Q2 2023, up 5% quarter-over-quarter.
  • 4 funds opened new PolyPid positions in Q2 2023 and 1 closed out, a net change of +3 holders.
  • The largest PolyPid buyer in Q2 2023 was Susquehanna International Group, an estimated $15K added.
  • The largest PolyPid seller in Q2 2023 was Connective Capital Management, an estimated $11.2K sold.

Based on aggregated 13F filings for Q2 2023.